Cancer Updates Dec Issue Final-16006_Cancer_Updates_Dec_Issue_F4_spreads | Page 2

1
BAYLOR CHARLES A. SAMMONS CANCER CENTERS
FROM THE MEDICAL
Cancer Research Studies at Baylor Charles A. Sammons Cancer Centers are
conducted through Baylor Scott & White Research Institute, Texas Oncology and
US Oncology. Each reviews, approves and conducts clinical trials independently.
DIRECTOR
There’s only one basic principle of self-defense—
you must apply the most effective weapon, as soon as
possible, to the most vulnerable target.
Bruce Lee
CONTENTS
Our referral, consult and information
line offers easy access for:
• Physician referrals
• Follow-up on patients to referring
physicians
• Medical records
• Information on clinical trials
• Specialized services
• New patient information, maps and
lodging information
Call 214.820.3535 Baylor University Medical Center and Baylor Institute for Immunology
Research are Creating New Immune Therapies Against Cancer
2
In this issue, we focus on utilizing our body’s own defense, our immune system, in the battle against
cancer. The American Society of Clinical Oncology named immunotherapy the “advance of the year” for
2016. In essence, we are engaging the weapons within to fight the enemy within.
Our arsenal in this battle is growing rapidly. With the Baylor Institute for Immunology Research (BIIR), we
have been studying dendritic cell cancer treatment vaccines for over 15 years. Building on the lessons
learned with the early dendritic cell melanoma trials, we have recently completed a trial in advanced
breast cancer and are accruing patients with pancreatic cancer. BIIR researchers are now developing
the next generation of “dendritic cell-engaging” vaccines that will obviate the need for ex vivo dendritic
cell manipulation, allowing the process to occur within the body.
Baylor University Medical Center and BIIR Get Global in
Development of Cancer Vaccines 5 Baylor Institute for Immunology Research is Developing a Vaccine
to Prevent Cancer in Patients Infected with HPV 7 For the First Time, Dendritic Cell Vaccine is Used in Patients with
Life-Threatening Triple-Negative Breast Cancer 9 WELCOME “Pancvax” Clinical Trial is First Study of Dendritic Cell Vaccine in
Pancreatic Cancer Patients at Baylor University Medical Center 11 Andrew Whiteley, MD
Internal Medicine/ Medical Oncology,
Baylor University Medical Center Vaccine-Based Clinical Trials Aim to Attack Difficult-to-Treat
Glioblastoma Brain Turmors at Baylor University Medical Center 13 Clinical Trials Using CAR T-Cells Start to Treat Blood Cancers ALL
and MCL at Baylor University Medical Center 16 Immune Checkpoint Inhibitors Make Progress Against Skin Cancer
and Lung Cancer 18 We have just begun to explore the potential of chimeric antigen receptor T-cell (CAR T-cell) therapies. At
Baylor University Medical Center at Dallas, we now have clinical trials using chimeric antigen receptor
T-cells (CAR T-cells) in acute lymphoblastic leukemia, mantle cell lymphoma and pancreatic cancer.
With all of these new immune approaches to cancer treatment, we would be remiss to forget one of
the first immunotherapy approaches to result in cancer cures—allogeneic hematopoietic stem cell
transplantation.
21 So as we look to find new approaches to combat cancer, we must look within, for the answer may be
closer than we thought.
EDITOR IN CHIEF:
Alan M. Miller, MD, PhD
Chief of Oncology, Baylor Scott &
White Health – North Texas
Medical Director, Baylor Charles A.
Sammons Cancer Center at Dallas
WRITERS AND ASSISTANT EDITORS:
Margaret Hinshelwood, PhD,
Taryn Pemberton, MHSM, MBA, and
Steve Yozwiak
Recent Publications from Baylor Sammons Cancer Center
Baylor Sammons Cancer Center Current Clinical Trials
Checkpoint inhibitors have rapidly moved from clinical trials to approved agents, with applications
in melanoma, non–small cell lung cancer, renal cell carcinoma and Hodgkin’s disease, with more
indications accruing rapidly. Antibody therapy, both “naked” and “load-bearing,” has been part of our
therapeutic arsenal since the approval of rituximab almost 20 years ago.
24
Alan M. Miller, MD, PhD
Chief of Oncology, Baylor Scott & White Health – North Texas
Medical Director, Baylor Charles A. Sammons Cancer Center at Dallas
Photography may include models or actors and may not represent actual patients. Physicians provide clinical services as members of the medical staff
at one of Baylor Scott & White Health’s subsidiary, community or affiliated medical centers and do not provide clinical services as employees or agents
of those medical centers, Baylor Health Care System, Scott & White Healthcare or Baylor Scott & White Health. ©2017 Baylor Scott & White Health.
SAMMONS_559_2016
To be removed from the mailing list, call 1.800.9BAYLOR.
Effective March 1, 2017, Dr. Miller is no longer with Baylor Scott & White Health.
Carlos Becerra, MD is now serving as the interim chief of oncology.